Syquant Capital SAS’s Abivax ABVX Stock Holding History

Syquant Capital SAS’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.26M	Sell	39,500 -3,000	-7%	-$340K	1.18%	8
2026 Q1	$4.73M	Buy	+42,500	New	+$5.03M	0.74%	14

Other funds holding ABVX

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Burns Matteson Capital Management Corning, New York $320M AUM 71.11% 1-Year Est. Return

QP Wealth Management Eatontown, New Jersey $70.1M AUM

Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Goldstein Advisors Madison, Wisconsin $1.09B AUM 23.69% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Syquant Capital SAS's ABVX Position: Q2 2026 in Review

Syquant Capital SAS reduced its Abivax (ABVX) stake by 7.1% in Q2 2026, selling an estimated $340K and leaving 39,500 shares worth $5.26M. The position accounts for 1.18% of the portfolio, ranked #8.

Syquant Capital SAS first reported a position in ABVX in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Syquant Capital SAS held 39,500 shares of Abivax worth $5.26M as of Q2 2026.
Syquant Capital SAS sold 3,000 Abivax shares in Q2 2026, an estimated $340K.
Abivax made up 1.18% of Syquant Capital SAS's portfolio in Q2 2026, its #8 holding.
Syquant Capital SAS first reported a position in Abivax in Q1 2026 and has held it in 2 quarters since.
25 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Syquant Capital SAS's 13F filing for Q2 2026, filed 9 Jul 2026.